NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ankyra

Ankyra

Private
Cambridge, MassachusettsHealthcare & Life Scienceswww.ankyratx.com

Last Round

Series B

Nov 12, 2021

Total Funding Raised

$50M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Ankyra is a biotechnology company specializing in innovative cancer therapy services that enhance the safety and effectiveness of cytokine immunotherapies for patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

anchored immunotherapycytokine therapytolododekin alfaANK-101immuno-oncologyinterleukin-12IL-12local drug deliveryreduced systemic toxicityintratumoral injectionanchored drug conjugatesolid tumor treatmentdrug depottumor microenvironmentfirst-in-class immunotherapyclinical-stage biotechlung cancerimmune checkpoint blockade

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ankyra Comps

Public and private peers based on sector, stage, and business model.

Ankyra comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ankyra Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 12, 2021
Series AMay 4, 2020

Key People

Founding team and executive leadership

Howard Kaufman

President And Chief Executive Officer

Executive Team

Ankyra Investors

Notable investors and investment history

Ankyra investors
InvestorRounds
GVSeries B
Fidelity Management & Research CompanySeries B
Borealis VenturesSeries B
Polaris PartnersSeries B, Series A
Sands CapitalSeries B
Spring Mountain CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Clinical presentations on novel IL-12 immunotherapy at AACR 2026.

  • Apr 16, 2026

    Will present at the AACR 2026 conference.

Ankyra Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ankyra Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ankyra's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range25
Year Founded2019
Last FundingNov 12, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.